Monoclonal Gammopathy of Renal Significance Clinical Trials

7 clinical trials for Monoclonal Gammopathy of Renal Significance across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS) — RECRUITING · PHASE2
• Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD — RECRUITING · PHASE2
• A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH — RECRUITING
• Daratumumab in Monoclonal Gammopathy of Renal Significance in Finland, DAMOCLES — TERMINATED · PHASE1
• Dara-BCD for Rare MGRS — NOT_YET_RECRUITING · PHASE2
• MGRS: Clinical-histological Features of a Multicenter Case Series — COMPLETED
• Diagnosis of MGRS in Patients With Paraproteinemias: Clinical, Anatomopathological and Pathophysiological Study — OTHER

Refine this search